Trial Profile
A single center phase I safety and immunogenicity study of Epimmune HIV-1 CTL epitope-based DNA vaccine (EP-HIV-1090) for immunotherapy of HIV-1 infected individuals receiving highly active antiretroviral therapy (HAART)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs EP 1090 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2005 New trial record.